FDA ap­proves ex-No­var­tis drug for Cush­ing’s dis­ease

Two months af­ter win­ning Eu­ro­pean ap­proval, a one-time No­var­tis or­phan drug for Cush­ing’s dis­ease has been OK’d by the FDA.

Is­tur­isa, known chem­i­cal­ly as os­ilo­dro­stat, has been ap­proved as a twice-dai­ly pill for those who have not un­der­gone the pi­tu­itary gland surgery of­ten used to treat Cush­ing’s dis­ease, or for those whose symp­toms per­sist af­ter the op­er­a­tion. No­var­tis sold the com­pound along­side two oth­er en­docrine drugs to the Ital­ian phar­ma Recor­dati last Ju­ly for $390 mil­lion, plus Is­tur­isa mile­stones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER